PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction.
November 9, 2023 – Lyon, France
PULSALYS SAS (“PULSALYS”), Deeptech innovations incubator and accelerator in Lyon and Saint-Etienne, and TheraPPI Bioscience SAS (“TheraPPI”), a preclinical biotechnology company developing small molecules that modify protein interactions in oncology, rare diseases and inflammation, today announced that they have entered into a license agreement for the development of drugs targeting a novel protein interaction in the Ras-MAPK pathway.
Under the license agreement, TheraPPI obtains exclusive and global rights for the development of novel drugs from compounds discovered within Dr Toufic Renno’s team at the Lyon Cancer Research Centre (CRCL: University Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in collaboration with the C3D technology platform of Lyon (Centre for Drug Discovery and Development) and with the support of Hospices Civils de Lyon. The Renno team has discovered a new therapeutic target, a protein-protein interaction (PPI) in the Ras-MAPK pathway, which is critical to cancer development and certain rare diseases. TheraPPI will develop two drug programs targeting this Ras-MAPK protein interaction in oncology and in rare diseases.
“PULSALYS is proud to support this ambitious project, led by TheraPPI Bioscience, which will enable to meet major healthcare challenges through new solutions developed for patients experiencing therapeutic failure. Furthermore, this project illustrates the cohesion and complementarity of the key players in the local oncology ecosystem, bringing together all stakeholders to boost TheraPPI Bioscience’s development,” emphasizes Sophie Jullian, President of PULSALYS. Luc Otten, CEO of TheraPPI added: “The exclusive rights on these novel compounds enable TheraPPI to continue building a portfolio of small molecules that target protein interactions against cancer resistance and provide a cure to rare diseases.”
Pursuant to the agreement, PULSALYS is entitled to receive milestone and royalty payments, based on the development of drugs targeting a novel Ras-MAPK protein interaction.
– ends –
Notes:
About PULSALYS (https://www.pulsalys.fr/) :
PULSALYS, Deeptech innovations incubator and accelerator in Lyon and Saint-Etienne, builds tomorrow’s innovative products and services by transforming scientific discoveries from the University of Lyon’s laboratories into economic opportunities for companies and startups. PULSALYS is the Technology Transfer Office (TTO) for the territory of Lyon – Saint-Etienne, created in December 2013 as part of the “Programme d’Investissements d’Avenir“ (PIA) initiated by the French government. Based on research innovations, PULSALYS builds and develops projects with high technological potential which constitute the basis for the creation of Deeptech startups, or competitive advantages for existing companies.
About TheraPPI Bioscience :
TheraPPI is preclinical-stage biotech company which develops protein interaction-modifying drugs to offer patients better treatments. TheraPPI’s two first programs target a novel MAPK protein interaction discovered by the founder team.
The prognosis of patients with advanced cancers remains poor. The MAPK signaling is hyperactivated in over 40% of human cancers and MAPK-activating mutations cause rare diseases. The efficacy of current MAPK Inhibitors is undercut by cancer resistance and by their inability to cure these rare diseases.
TheraPPI’s lead program in oncology revolutionizes RAS-MAPK targeting: the new mode of action leverages three mechanisms with direct killing cancer cells, no resistance induction and activation of an anti-tumoral immune response.
TheraPPI’s lead program aims to obtain a high rate of clinical responses, to circumvent cancer resistance and to improve the response of immunotherapies and thus to offer a better prognosis to patients with advanced cancer.
Read more: https://tppibio.com/
Follow us on LinkedIn: https://www.linkedin.com/therappi-bioscience/
Forward Looking Statements:
This press release includes forward-looking statements and assumptions which reflect the management’s current views of future events and operations. These forward-looking statements involve certain significant risks and uncertainties, and actual results may (negatively or positively) differ substantially from the forward-looking statements described explicitly or implicitly by TheraPPI.
Contacts:
TheraPPI Bioscience
Luc Otten
CEO and co-founder
Pulsalys
Sylvain Duc
Communication